Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (18294)
All Articles published online
|
Publishing Process of This Article
|
Aug 7, 2016 (publication date) through Feb 14, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Shayto RH, Abou Mrad R, Sharara AI. Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol 2016; 22(29): 6638-6651 [PMID: PMC4970477 DOI: 10.3748/wjg.v22.i29.6638] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i29/6638.htm |
| Number | Citing Articles |
| 1 |
Hourieh Kalhor, Solmaz Sadeghi, Hoda Abolhasani, Reyhaneh Kalhor, Hamzeh Rahimi. Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches. Journal of Biomolecular Structure and Dynamics 2022; 40(3): 1299 doi: 10.1080/07391102.2020.1824816
|
| 2 |
Kamesh Gupta, Harparam Singh Ghuman, Shivani Vijay Handa. Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile. Clinical Medicine Insights: Gastroenterology 2017; 10: 117955221772890 doi: 10.1177/1179552217728905
|
| 3 |
Fernando Magdaleno, Maximilian Joseph Brol, Robert Schierwagen, Frank Erhard Uschner, Michael Zwick, Jonel Trebicka. The Human Gut-Liver-Axis in Health and Disease. 2019; : 235 doi: 10.1007/978-3-319-98890-0_14
|
| 4 |
Elesa Poteres, Nathaniel Hubert, Sudeep Poludasu, Gabriella Brigando, Julia Moore, Kelly Keeler, Allison Isabelli, Iara Cassandra V. Ibay, Lauren Alt, Matthew Pytynia, Mae Ciancio, Kristina Martinez-Guryn. Selective Regional Alteration of the Gut Microbiota by Diet and Antibiotics. Frontiers in Physiology 2020; 11 doi: 10.3389/fphys.2020.00797
|
| 5 |
Anna Piccin, Marco Gulotta, Stefano di Bella, Paola Martingano, Lory Saveria Crocè, Mauro Giuffrè. Diverticular Disease and Rifaximin: An Evidence-Based Review. Antibiotics 2023; 12(3): 443 doi: 10.3390/antibiotics12030443
|
| 6 |
Ji Won Han, Da In Kim, Hee Chul Nam, U Im Chang, Jin Mo Yang, Do Seon Song. Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis. Clinical and Molecular Hepatology 2022; 28(2): 219 doi: 10.3350/cmh.2021.0082
|
| 7 |
Kensuke Kitsugi, Kazuhito Kawata, Hidenao Noritake, Takeshi Chida, Kazuyoshi Ohta, Jun Ito, Shingo Takatori, Maho Yamashita, Tomohiko Hanaoka, Masahiro Umemura, Moe Matsumoto, Takafumi Suda. Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation. Journal of Clinical Medicine 2023; 12(6): 2210 doi: 10.3390/jcm12062210
|
| 8 |
Saumya Jayakumar, Rohit Loomba. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Alimentary Pharmacology & Therapeutics 2019; 50(2): 144 doi: 10.1111/apt.15314
|
| 9 |
S. K. Zyryanov, E. A. Baybulatova. Rifaximin-Alpha and Other Crystalline Forms of Rifaximin: Are There Any Differences?. Antibiotics and Chemotherapy 2020; 65(7-8): 52 doi: 10.37489/0235-2990-2020-65-7-8-52-62
|
| 10 |
Allison Ferris, Polina Gaisinskaya, Neilanjan Nandi. Approach to Diarrhea. Primary Care: Clinics in Office Practice 2023; 50(3): 447 doi: 10.1016/j.pop.2023.03.010
|
| 11 |
Nesreen Nabil Omar, Rasha A. Mosbah, Wedad S. Sarawi, Marwa Medhet Rashed, Amira M. Badr. Rifaximin Protects against Malathion-Induced Rat Testicular Toxicity: A Possible Clue on Modulating Gut Microbiome and Inhibition of Oxidative Stress by Mitophagy. Molecules 2022; 27(13): 4069 doi: 10.3390/molecules27134069
|
| 12 |
Maria J. Duarte, Phyllis C. Tien, Ma Somsouk, Jennifer C. Price. The human microbiome and gut–liver axis in people living with HIV. Current HIV/AIDS Reports 2023; 20(3): 170 doi: 10.1007/s11904-023-00657-x
|
| 13 |
Peter Dellatore, Maggie Cheung, Noah Y. Mahpour, Augustine Tawadros, Vinod K. Rustgi. Clinical Manifestations of Hepatic Encephalopathy. Clinics in Liver Disease 2020; 24(2): 189 doi: 10.1016/j.cld.2020.01.010
|
| 14 |
Guilhem Royer, Fréderic Fourreau, Camille Gomart, Audrey Maurand, Bruno Hacquin, David Ducellier, Florence Cizeau, Stéphane Lo, Catherine Cordonnier-Jourdin, Mélanie Mercier-Darty, Jean-Winoc Decousser. Outbreak of an Uncommon Rifampin-resistant blaNDM-1Citrobacter amalonaticus Strain in a Digestive Rehabilitation Center: The Putative Role of Rifaximin. Clinical Infectious Diseases 2020; 71(5): 1331 doi: 10.1093/cid/ciz1172
|
| 15 |
Adrianna M. Turner, Lucy Li, Ian R. Monk, Jean Y. H. Lee, Danielle J. Ingle, Stephanie Portelli, Norelle L. Sherry, Nicole Isles, Torsten Seemann, Liam K. Sharkey, Calum J. Walsh, Gavin E. Reid, Shuai Nie, Bart A. Eijkelkamp, Natasha E. Holmes, Brennan Collis, Sara Vogrin, Andreas Hiergeist, Daniela Weber, Andre Gessner, Ernst Holler, David B. Ascher, Sebastian Duchene, Nichollas E. Scott, Timothy P. Stinear, Jason C. Kwong, Claire L. Gorrie, Benjamin P. Howden, Glen P. Carter. Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin. Nature 2024; 635(8040): 969 doi: 10.1038/s41586-024-08095-4
|
| 16 |
Emma Padilla, Lluis Oms, Elena Espejo, Laura Gómez, Lurdes Pagespetit, Núria Boada, Feliu Bella, Josefa Pérez. Rifampin Resistance in Staphylococci after Rifaximin Intake for Surgical Prophylaxis in Elective Colorectal Surgery. Antimicrobial Agents and Chemotherapy 2018; 62(12) doi: 10.1128/AAC.01353-18
|
| 17 |
Davide Sometti, Chiara Ballan, Huiying Wang, Christoph Braun, Paul Enck. Effects of the antibiotic rifaximin on cortical functional connectivity are mediated through insular cortex. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-83994-4
|
| 18 |
Tarek Mazzawi. Gut Microbiota Manipulation in Irritable Bowel Syndrome. Microorganisms 2022; 10(7): 1332 doi: 10.3390/microorganisms10071332
|
| 19 |
Marwa Salih Al-Naimi, Ahmed R. Abu-Raghif, Hayder Adnan Fawzi. Novel therapeutic effects of rifaximin in combination with methylprednisolone for LPS-induced oxidative stress and inflammation in mice: An in vivo study. Toxicology Reports 2024; 13: 101808 doi: 10.1016/j.toxrep.2024.101808
|
| 20 |
Yu Wang, Jiong Tang, Su Zhou, Tian-Tian Liang, Fang-Fang Wang, Hong Ning. Effectiveness and Safety of Rifaximin-Containing Regimens for Helicobacter pylori Eradication: Systematic Review – Are They Potential Eradication Regimens?. Infection and Drug Resistance 2022; : 3733 doi: 10.2147/IDR.S371131
|
| 21 |
A. A. Sheptulin, S. S. Kardasheva, A. A. Kurbatova. Features of etiology, clinical picture, diagnosis and treatment of travelers’ diarrhea. Clinical Medicine (Russian Journal) 2023; 101(2-3): 137 doi: 10.30629/0023-2149-2023-101-2-3-137-140
|
| 22 |
Jan Bednarsch, Zoltan Czigany, Sven H. Loosen, Lara Heij, Lorenz Ruckgaber, Henning Maes, Jan-Pit Krause, Matthias Reen, Beata Toteva, Theresa Vosdellen, Philipp Bruners, Sven Arke Lang, Tom Florian Ulmer, Christoph Roderburg, Tom Luedde, Ulf Peter Neumann. Perioperative rifaximin is not associated with enhanced functional and volumetric recovery after major liver resection. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-97442-w
|
| 23 |
Marina Ferrer, Mònica Aguilera, Vicente Martinez. Effects of Rifaximin on Luminal and Wall-Adhered Gut Commensal Microbiota in Mice. International Journal of Molecular Sciences 2021; 22(2): 500 doi: 10.3390/ijms22020500
|
| 24 |
Ciara Wright, Melissa Dooley, Heather Leeson. Eradication of small intestinal bacterial overgrowth in irritable bowel syndrome using herbal therapy: A case report. International Journal of Functional Nutrition 2021; 2(5) doi: 10.3892/ijfn.2021.23
|
| 25 |
El-Sayed Ibrahim, Ayman Alsebaey, Hassan Zaghla, Sabry Moawad Abdelmageed, Khalid Gameel, Eman Abdelsameea. Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome. European Journal of Gastroenterology & Hepatology 2017; 29(11): 1247 doi: 10.1097/MEG.0000000000000967
|
| 26 |
Shreyashi Pal, Ruhi Arisha, Papiya Mitra Mazumder. A systematic review of preclinical studies targeted toward the management of co-existing functional gastrointestinal disorders, stress, and gut dysbiosis. Naunyn-Schmiedeberg's Archives of Pharmacology 2025; 398(1): 25 doi: 10.1007/s00210-024-03332-z
|
| 27 |
Marina Fortea, Mercé Albert-Bayo, Mar Abril-Gil, John-Peter Ganda Mall, Xavier Serra-Ruiz, Alejandro Henao-Paez, Elba Expósito, Ana María González-Castro, Danila Guagnozzi, Beatriz Lobo, Carmen Alonso-Cotoner, Javier Santos. Present and Future Therapeutic Approaches to Barrier Dysfunction. Frontiers in Nutrition 2021; 8 doi: 10.3389/fnut.2021.718093
|
| 28 |
Tesemma Sileshi, Gosaye Mekonen, Eyasu Makonnen, Eleni Aklillu. Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review. Pharmacogenomics and Personalized Medicine 2022; : 561 doi: 10.2147/PGPM.S363058
|
| 29 |
Ashley Oliver, Mark Wong, Chelsea Sanchez. Role of Rifaximin in Spontaneous Bacterial Peritonitis Prevention. Southern Medical Journal 2018; 111(11): 660 doi: 10.14423/SMJ.0000000000000887
|
| 30 |
Albert Eugene Pekary, Albert Sattin. Rifaximin modulates TRH and TRH-like peptide expression throughout the brain and peripheral tissues of male rats. BMC Neuroscience 2022; 23(1) doi: 10.1186/s12868-022-00694-z
|
| 31 |
Amy Kassebaum-Ladewski. Irritable Bowel Syndrome-Strategies for Diagnosis and Management. Physician Assistant Clinics 2021; 6(4): 637 doi: 10.1016/j.cpha.2021.05.008
|
| 32 |
Jinsheng Wang, Lei Zhang, Xiaohua Hou. Efficacy of rifaximin in treating with small intestine bacterial overgrowth: a systematic review and meta-analysis. Expert Review of Gastroenterology & Hepatology 2021; 15(12): 1385 doi: 10.1080/17474124.2021.2005579
|
| 33 |
Herbert L. DuPont, Graeme N. Forrest. The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review. Clinical Microbiology Reviews 2023; 36(4) doi: 10.1128/cmr.00039-23
|
| 34 |
|
| 35 |
|
| 36 |
Julie Ann Tolefree, Abigail Joy Garcia, Jenee Farrell, Vik Meadows, Lindsey Kennedy, Laura Hargrove, Jennifer Demieville, Nicole Francis, Julia Mirabel, Heather Francis. Alcoholic liver disease and mast cells: What's your gut got to do with it?. Liver Research 2019; 3(1): 46 doi: 10.1016/j.livres.2019.02.002
|
| 37 |
L. S. Оrеshkо, E. A. Semenova. Clinical experience with the use of the intestinal antibiotic Rifaximin for celiac disease. Medical Council 2019; (14): 94 doi: 10.21518/2079-701X-2019-14-94-98
|
| 38 |
Anna Gudan, Katarzyna Kozłowska-Petriczko, Ewa Wunsch, Tomasz Bodnarczuk, Ewa Stachowska. Small Intestinal Bacterial Overgrowth and Non-Alcoholic Fatty Liver Disease: What Do We Know in 2023?. Nutrients 2023; 15(6): 1323 doi: 10.3390/nu15061323
|
| 39 |
Mazen Elsheikh, Ahmed El Sabagh, Islam B Mohamed, Megha Bhongade, Manal M Hassan, Prasun Kumar Jalal. Frailty in end-stage liver disease: Understanding pathophysiology, tools for assessment, and strategies for management. World Journal of Gastroenterology 2023; 29(46): 6028-6048 doi: 10.3748/wjg.v29.i46.6028
Abstract(540) |
Core Tip(584) |
Full Article(HTML)(4032)
|
Full Article with Cover (PDF)-1369K(129)
|
Full Article (Word)-615K(46)
|
Audio-631K(5)
|
Peer-Review Report-216K(72)
|
Answering Reviewers-281K(79)
|
Full Article (PDF)-1145K(251)
|
Full Article (XML)-412K(59)
|
Times Cited (4)
|
Total Visits (7684)
|
Open
|
| 40 |
Rommel Zerpa Alamo, Eamonn M.M. Quigley. Irritable bowel syndrome and colonic diverticular disease. Current Opinion in Gastroenterology 2019; 35(1): 27 doi: 10.1097/MOG.0000000000000499
|
| 41 |
Daniel Anthony DiLeo, Tolga Gidener, Ayse Aytaman. Chronic Liver Disease in the Older Patient—Evaluation and Management. Current Gastroenterology Reports 2023; 25(12): 390 doi: 10.1007/s11894-023-00908-2
|
| 42 |
Anitha Sriram, Suma Tangirala, Srividya Atmakuri, Sajid Hoque, Sheela Modani, Saurabh Srivastava, Srushti Mahajan, Indrani Maji, Rahul Kumar, Dharmendra Khatri, Jitender Madan, Pankaj Kumar Singh. Budding Multi-matrix Technology—a Retrospective Approach, Deep Insights, and Future Perspectives. AAPS PharmSciTech 2021; 22(8) doi: 10.1208/s12249-021-02133-4
|
| 43 |
Carlo Brogna, Simone Cristoni, Barbara Brogna, Domenico Rocco Bisaccia, Giuliano Marino, Valentina Viduto, Luigi Montano, Marina Piscopo. Toxin-like Peptides from the Bacterial Cultures Derived from Gut Microbiome Infected by SARS-CoV-2—New Data for a Possible Role in the Long COVID Pattern. Biomedicines 2022; 11(1): 87 doi: 10.3390/biomedicines11010087
|
| 44 |
Nida Iqbal, Amber Bano, Daim Asif Raja, Ali Raza, Rabia Ilyas, Rafia Akhlaq, Imran Saleem, Ayaz Ahmed, Syed Ghulam Musharraf, Muhammad Imran Malik. Enhancement in the antibacterial activity of Rifaximin by delivery through gelatin nanoparticles. Drug Development and Industrial Pharmacy 2024; 50(9): 789 doi: 10.1080/03639045.2024.2405622
|